@article{ref1,
title="Recommendations for reducing the risk of cannabis use-related adverse psychosis outcomes: a public mental health-oriented evidence review",
journal="Journal of dual diagnosis",
year="2023",
author="Fischer, Benedikt and Hall, Wayne and Fidalgo, Thiago M. and Hoch, Eva and Foll, Bernard Le and Medina-Mora, Maria-Elena and Reimer, Jens and Tibbo, Philip G. and Jutras-Aswad, Didier",
volume="ePub",
number="ePub",
pages="ePub-ePub",
abstract="OBJECTIVE: Cannabis use is increasingly normalized; psychosis is a major adverse health outcome. We reviewed evidence on cannabis use-related risk factors for psychosis outcomes at different stages toward recommendations for risk reduction by individuals involved in cannabis use. <br><br>METHODS: We searched primary databases for pertinent literature/data 2016 onward, principally relying on reviews and high-quality studies which were narratively summarized and quality-graded; recommendations were developed by international expert consensus. <br><br>RESULTS: Genetic risks, and mental health/substance use problem histories elevate the risks for cannabis-related psychosis. Early age-of-use-onset, frequency-of-use, product composition (i.e., THC potency), use mode and other substance co-use all influence psychosis risks; the protective effects of CBD are uncertain. Continuous cannabis use may adversely affect psychosis-related treatment and medication effects. Risk factor combinations further amplify the odds of adverse psychosis outcomes. <br><br>CONCLUSIONS: Reductions in the identified cannabis-related risks factors-short of abstinence-may decrease risks of related adverse psychosis outcomes, and thereby protect cannabis users' health.<p /> <p>Language: en</p>",
language="en",
issn="1550-4263",
doi="10.1080/15504263.2023.2226588",
url="http://dx.doi.org/10.1080/15504263.2023.2226588"
}